C12Y301/21

Gene editing method using virus

Provided is a method of inserting a polynucleotide sequence into a genome of a cell. The method comprises: generating a double-strand break at a target site of the genome; and introducing into the cell a virus. The virus comprises a nucleic acid comprising the polynucleotide sequence to be inserted or the complementary sequence thereof. The nucleic acid does not comprise a homologous arm or comprises very short (5˜25 bp) homologous arms corresponding to the target site. Also provided herein is a composition for inserting a polynucleotide sequence into a genome of a cell. The composition comprises a site-specific nuclease capable of generating a DNA double-strand break at a target site of the genome and a virus comprising a nucleic acid comprising the polynucleotide sequence or the complementary sequence thereof.

ENZYME COMPOSITIONS AND USES THEREOF
20230159861 · 2023-05-25 · ·

The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates to use of compositions comprising such enzymes in cleaning processes.

Methods and products for transfecting cells

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

METHODS FOR REMOVAL OF ADAPTOR DIMERS FROM NUCLEIC ACID SEQUENCING PREPARATIONS
20230074210 · 2023-03-09 ·

Sequencing adaptors and methods are provided for preparation of polynucleotides for sequencing. The sequencing adaptors contain a portion of a recognition sequence for a methyl-dependent endonuclease. Unwanted adaptor dimers that form during ligation of adaptors to target polynucleotides produce a complete restriction sequence and are cleaved by the endonuclease, followed by exonuclease digestion, thereby removing the dimers.

CAS9 Fusion Proteins and Related Methods

Disclosed are recombinant Cas9 proteins, methods of production, and methods of use for targeted DNA deletions, DNA insertions, or both in a eukaryotic genome. An assay system for evaluating the ability of the recombinant Cas9 proteins for targeted DNA deletions, DNA insertions, or both in a eukaryotic genome is also disclosed.

METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
20230181698 · 2023-06-15 ·

A method of preventing transmission of a retrovirus from a mother to her offspring, by administering to the mother a therapeutically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and the two or more different multiplex gRNAs, wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of the virus that is unique from the genome of the host cell, cleaving a double strand of the proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease, cleaving a double strand of the proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease, excising an entire HIV-I proviral genome, eradicating the HIV-I proviral DNA from the host cell, and preventing transmission of the proviral DNA to the offspring.

Materials and methods for the synthesis of error-minimized nucleic acid molecules

The present invention provides materials and methods useful for error correction of nucleic acid molecules. In one embodiment of the invention, a first plurality of double-stranded nucleic acid molecules having a nucleotide mismatch are fragmented by exposure to a molecule having unidirectional mismatch endonuclease activity. The nucleic acid molecules are cut at the mismatch site or near the mismatch site, leaving a double-stranded nucleic acid molecule having a mismatch at the end or near end of the molecule. The nucleic acid molecule is then exposed to a molecule having unidirectional exonuclease activity to remove the mismatched nucleotide. The missing nucleotides can then be filled in by the action of, e.g., a molecule having DNA polymerase activity. The result is double-stranded nucleic acid molecules with a decreased frequency of nucleotide mismatches. Also provided are novel nucleic acid sequences encoding mismatch endonucleases, polypeptides encoded thereby, as well as nucleic acid constructs, transgenic cells, and various compositions thereof.

ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
20210380983 · 2021-12-09 ·

Materials and methods for gene targeting using Clustered Regularly Interspersed Short Palindromic Repeats/CRISPR-associated (CRISPR/Cas) systems are provided herein.

METHODS AND PRODUCTS FOR TRANSFECTING CELLS
20230242943 · 2023-08-03 ·

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3

Methods for treating a subject with cancer, including administering to the subject an effective amount of an inhibitor of DNAse1L3 and an effective amount of radiation therapy are provided. In some examples, the methods involve enhancing or inducing response of tumor-associated immune cells in the subject, including administering to the subject an effective amount of radiation therapy, and administering to the subject an effective amount of an inhibitor of DNAse1L3, thereby enhancing or inducing the response of tumor-associated immune cells in the subject. In some examples, the tumor-associated immune cells comprise dendritic cells or macrophages.